Nuvini Group Announces Launch of NuviniAI Index - Nvni Group (NASDAQ:NVNI)

Nvni Group Ltd (NVNI) furnished an SEC Form 6-K — earnings release. Exhibit 99.2 NUVINI NASDAQ: NVNI FOR IMMEDIATE RELEASE Nuvini Group Reports First Half 2026 Results: Operating Income of R$19.6 Million, Positive Operating Cash Flow, Net Loss Reduced 76% Gross margin expands to 68%; G&A down 25%; Company advances capital restructuring SÃO PAULO

Nvni Group Limited (Nasdaq: NVNI) said it is in the final stretch of acquiring a 51% controlling interest in a holding company for Beyondsoft’s U.S., Brazil and Singapore consulting/services business. The company expects pro forma FY2025 revenue of about $148M, serving 22,400+ customers. Nuvini cited Target incorporation, near-complete restructuring, shareholder approval, and renewal/assignment of a key client contract, with remaining regulatory and agreement steps pending.

BNP Paribas downgraded Vail Resorts (MTN) to Neutral, lowering its price target to $135 due to a 5% decline in pass sales and weather-related concerns. MTN offers a 6.35% dividend yield but has a high payout ratio of 2.04. The stock is modestly undervalued with a GF Value™ of $182.35. MTN has a strong GF Score™ of 85, reflecting robust profitability and growth, but faces financial strength challenges. Insiders and gurus have shown confidence in the stock.

Johnson & Johnson (JNJ) reported positive Phase 3 trial results for CAPLYTA in treating acute manic episodes in adults with bipolar I disorder. The drug showed significant improvement in mania symptoms compared to placebo, with a 4.8-point greater reduction in YMRS scores. A second Phase 3 study has completed enrollment, with data analysis ongoing. JNJ stated CAPLYTA's safety profile was consistent with previous findings.

Lockheed Martin (LMT) received a $76.6M contract modification for the Trident II D5 Life Extension 2 program, supporting missile modernization. The U.S. Navy's focus on strategic deterrence may drive long-term demand for LMT's capabilities. LMT's shares have risen 11.1% year-over-year, trading at a 16.51X forward P/E, below its industry average of 29.17X.

Oppenheimer analyst Suraj Kalia reduced the price target for Boston Scientific (BSX) to $65 from $85, maintaining an Outperform rating. The firm also lowered its FY26 and FY27 estimates, citing a cybersecurity breach and competitive pressures in LAAC/EP.